natgillin/translations-raw huggingface dataset:
The following adverse reactions, listed in Table 1, have been accumulated both from a pooled data of eleven double-blind clinical trials consisting of 3230 patients (1810 treated with Stalevo or entacapone combined with levodopa/DDC inhibitor, and 1420 treated with placebo combined with levodopa/DDC inhibitor or cabergoline combined with levodopa/ DDC inhibitor), and from the post- marketing data since the introduction of entacapone into the market for the combination use of entacapone with levodopa/DDC inhibitor.
Neželeni učinki v nadaljevanju, našteti v preglednici 1, so bili zbrani iz združenih podatkov enajstih dvojno slepih kliničnih preskušanj, ki so zajela 3.230 bolnikov (1.810 zdravljenih z zdravilom Stalevo ali entakaponom v kombinaciji z levodopo/zaviralcem dekarboksilaze, in 1.420 zdravljenih s placebom v kombinaciji z levodopo/zaviralcem dekarboksilaze ali kabergolinom v kombinaciji z levodopo/zaviralcem dekarboksilaze), in iz podatkov v obdobju trženja, od uvedbe entekapona za kombinirano uporabo z levodopo/zaviralcem dekarboksilaze.
The following adverse reactions, listed in Table 1, have been accumulated both from a pooled data of eleven double-blind clinical trials consisting of 3230 patients (1810 treated with Stalevo or entacapone combined with levodopa/DDC inhibitor, and 1420 treated with placebo combined with levodopa/DDC inhibitor or cabergoline combined with levodopa/ DDC inhibitor), and from the post- marketing data since the introduction of entacapone into the market for the combination use of entacapone with levodopa/DDC inhibitor.
Neželeni učinki v nadaljevanju, našteti v preglednici 1, so bili zbrani iz združenih podatkov iz enajstih dvojno slepih kliničnih preskušanj, ki so zajela 3.230 bolnikov (1.810 zdravljenih z zdravilom Stalevo ali entakaponom v kombinaciji z levodopo/zaviralcem dekarboksilaze, in 1.420 zdravljenih s placebom v kombinaciji z levodopo/zaviralcem dekarboksilaze ali kabergolinom v kombinaciji z levodopo/zaviralcem dekarboksilaze), in iz podatkov v obdobju trženja, od uvedbe entekapona za kombinirano uporabo z levodopo/zaviralcem dekarboksilaze.
The following adverse reactions, listed in Table 1, have been accumulated from clinical studies and post-marketing reports following predominantly chronic treatment with zoledronic acid:
Naslednji neželeni učinki, navedeni v preglednici 1, so zbrani iz kliničnih študij in iz poročanj v obdobju po prihodu zdravila na trg, ki so sledili pretežno kroničnemu zdravljenju z zoledronsko kislino:
The following adverse reactions, listed in table 1, have been accumulated from clinical trials with Spectrila in 125 children with newly diagnosed acute lymphoblastic leukaemia as well as post- marketing experience with other E. coli-derived asparaginase preparations in children and adults.
Naslednji neželeni učinki, navedeni v preglednici 1, so bili zbrani v kliničnih preskušanjih z zdravilom Spectrila pri 125 otrocih z na novo diagnosticirano akutno limfoblastno levkemijo in iz izkušenj v obdobju trženja drugih zdravil z asparaginazo, ki izvirajo iz E. coli, pri otrocih in odraslih.
The following adverse reactions, listed in Table 2, have been accumulated from clinical studies and post-marketing reports following predominantly chronic treatment with 4 mg zoledronic acid:
Naslednji neželeni učinki, navedeni v preglednici 1, so zbrani iz kliničnih študij in iz poročanj v obdobju po prihodu zdravila na trg, ki so sledili pretežno kroničnemu zdravljenju s 4-miligramsko zoledronsko kislino:
The following adverse reactions, listed in Table 2, have been accumulated from clinical studies and post-marketing reports following predominantly chronic treatment with zoledronic acid:
Naslednji neželeni učinki, navedeni v preglednici 2, so zbrani iz kliničnih študij in iz poročanj v obdobju po prihodu zdravila na trg, ki so sledili pretežno kroničnemu zdravljenju z zoledronsko kislino:
The following age-adjusted dosing prophylaxis regimen is recommended for infants 0 - 12 months of age (see Section 5.2 for exposure simulation):
Priporočena shema za preprečevanje bolezni glede na starost za dojenčke, stare od 0 do 12 mesecev (za simulacijo izpostavljenosti glejte poglavje 5.2), je:
The following age-adjusted dosing prophylaxis regimen is recommended for infants 0 – 12 months of age:
Priporočena shema za preprečevanje bolezni, glede na starost za dojenčke, stare od 0 do 12 mesecev, je:
The following agents may reduce the hypoglycaemic effect of nateglinide: diuretics, corticosteroids, and beta2 agonists.
Hipoglikemično delovanje nateglinida lahko zmanjšajo sledeča sredstva: diuretiki, kortikosteroidi in agonisti adrenergičnih receptorjev beta2.
The following agents may reduce the hypoglycaemic effect of nateglinide: diuretics, corticosteroids, beta2 agonists, somatropin, somatostatin analogues (e.g. lanreotide, octreotide), rifampin, phenytoin and St John’s wort.
Hipoglikemično delovanje nateglinida lahko zmanjšajo sledeča sredstva: diuretiki, kortikosteroidi, agonisti adrenergičnih receptorjev beta2, somatotropin, analogi somatostatina (na primer lanreotid, oktreotid), rifampin, fenitoin in šentjanževka.
The following application-site drug-related adverse reactions were reported during clinical studies in patients with KS.
KS bolniki so med kliničnimi študijami poročali o sledečih neželenih učinkih zdravila na mestu aplikacije.
The following are adverse reactions reported in patients receiving fosaprepitant in clinical studies or postmarketing that have not been reported with aprepitant as described above:
Spodaj so našteti neželeni učinki, o katerih so poročali pri bolnikih, ki so v kliničnih študijah ali v obdobju trženja zdravila prejeli fosaprepitant, in o katerih niso poročali pri aprepitantu:
The following are adverse reactions that were reported in tasimelteon-treated adult patients, derived from patient trials in 1772 patients treated with tasimelteon.
V nadaljevanju so navedeni neželeni učinki, o katerih so poročali pri odraslih bolnikih, zdravljenih s tasimelteonom, iz preskušanj, v katerih je sodelovalo 1772 bolnikov, ki so prejemali tasimelteon.
The following are all ADRs that were reported with paliperidone by frequency category estimated from TREVICTA and 1-monthly paliperidone palmitate injectable clinical trials.
V nadaljevanju so po pogostnosti navedeni vsi neželeni učinki, o katerih so poročali pri uporabi paliperidona v kliničnih preskušanjih zdravila TREVICTA in 1-mesečnimi injekcijami paliperidonijevega palmitata.
The following are all ADRs that were reported with paliperidone by frequency category estimated from Xeplion clinical trials.
O pogostnosti naslednjih neželenih učinkov paliperidona so poročali v kliničnih preskušanjih zdravila Xeplion.
The following are all the ADRs that were reported in clinical trials and postmarketing experience with paliperidone by frequency category estimated from INVEGA clinical trials in adults.
V spodnji tabeli so navedeni vsi neželeni učinki o katerih so poročali v kliničnih preskušanjih in v obdobju trženja s paliperidonom po pogostnostih, ocenjenih v kliničnih preskušanjih zdravila INVEGA pri odraslih .
The following are precautions for use of Osigraft to be discussed with your doctor.
V nadaljevanju so navedeni previdnostni ukrepi pri uporabi zdravila Osigraft, o katerih se posvetujte s svojim zdravnikom.
The following are reasons why ARICLAIM may not be suitable for you.
Spodaj so našteti razlogi, zaradi katerih morda zdravilo ARICLAIM za vas ni ustrezno.
The following are reasons why Duloxetine Lilly may not be suitable for you.
Spodaj so našteti razlogi, zaradi katerih morda zdravilo Duloxetine Lilly za vas ni ustrezna.
The following are reasons why Xeristar may not be suitable for you.
Spodaj so našteti razlogi, zaradi katerih morda zdravilo Xeristar za vas ni ustrezno.
The following are reasons why YENTREVE may not be suitable for you.
Spodaj so našteti razlogi, zaradi katerih morda zdravilo YENTREVE za vas ni ustrezno.
The following are suitable test meals:
Primerni testni obroki so:
The following are the important identified risks with zoledronic acid in the approved indications: Renal function impairment, osteonecrosis of the jaw, acute phase reaction, hypocalcaemia, , atrial fibrillation, anaphylaxis , interstitial lung disease.
Pri uporabi zoledronske kisline za odobrene indikacije so ugotovili naslednja pomembna tveganja: moteno delovanje ledvic, osteonekrozo čeljustnic, reakcijo akutne faze, hipokalciemijo, atrijsko fibrilacijo, anafilaksijo, intersticijsko bolezen pljuč.
The following are the important identified risks with zoledronic acid in the approved indications: Renal function impairment, osteonecrosis of the jaw, acute phase reaction, hypocalcaemia, atrial fibrillation, anaphylaxis, interstitial lung disease.
Pri uporabi zoledronske kisline za odobrene indikacije so ugotovili naslednja pomembna tveganja: moteno delovanje ledvic, osteonekrozo čeljusti, reakcijo akutne faze, hipokalciemijo, atrijsko fibrilacijo, anafilaksijo, intersticijsko bolezen pljuč.
The following are the important identified risks with zoledronic acid in the approved indications: Renal function impairment, osteonecrosis of the jaw, acute phase reaction, hypocalcaemia, atrial fibrillation, anaphylaxis, interstitial lung disease.
Pri uporabi zoledronske kisline za odobrene indikacije so ugotovili naslednja pomembna tveganja: moteno delovanje ledvic, osteonekrozo čeljustnic, reakcijo akutne faze, hipokalciemijo, , atrijsko fibrilacijo, anafilaksijo, intersticijsko bolezen pljuč.
The following are the important identified risks with zoledronic acid in the approved indications: Renal function impairment, osteonecrosis of the jaw, acute phase reaction, hypocalcaemia, ocular adverse events, atrial fibrillation, anaphylaxis.
Pri uporabi zoledronske kisline za odobrene indikacije so ugotovili naslednja pomembna tveganja: moteno delovanje ledvic, osteonekrozo čeljustnic, reakcijo akutne faze, hipokalciemijo, očesne neželene dogodke, atrijsko fibrilacijo, anafilaksijo.
The following are the most common and important incidences of adverse reactions related to 421 patients with metastatic adenocarcinoma of the pancreas who were treated with 125 mg/m2 Abraxane in combination with gemcitabine at a dose of 1000 mg/m2 given on Days 1, 8 and 15 of each 28-day cycle in the phase III clinical study.
V nadaljevanju so navedena najpogostejša in najpomembnejša pojavljanja neželenih učinkov pri 421 bolnikih z metastatskim adenokarcinomom trebušne slinavke, zdravljenih s 125 mg/m2 zdravila Abraxane v kombinaciji z gemcitabinom v odmerku 1.000 mg/m2 1., 8. in 15. dan vsakega 28- dnevnega cikla v klinični študiji faze III.
The following can all be signs of serious side effects:
Naslednji znaki so lahko znaki resnih neželenih učinkov:
The following categories are used to rank the adverse reactions by frequency of occurrence: very common ( ≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥ 1/10,000 to <1/1,000); and very rare (<1/10,000), including isolated reports.
Neželeni učinki so razvrščeni v naslednje kategorije na podlagi pogostnosti: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000) in zelo redki (< 1/10.000) vključno s posameznimi primeri.
The following categories are used to rank the adverse reactions by frequency of occurrence: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to
Za razvrščanje neželenih učinkov po pogostnosti pojavljanja se uporabljajo naslednje kategorije: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1,000 do <1/100); redki (≥1/10,000 do
The following categories are used to rank the undesirable effects by frequency of occurrence: very common (1/10); common (1/100 to 1/10); uncommon (1/1000 to 1/100); rare (1/10,000 to
Za razvrstitev pogostnosti pojavljanja neželenih učinkov se uporabljajo naslednje kategorije: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do
The following changes, observed in rats and macaques receiving the irbesartan/hydrochlorothiazide combination at 10/10 and 90/90 mg/kg/day, were also seen with one of the two medicinal products alone and/or were secondary to decreases in blood pressure (no significant toxicologic interactions were observed):
na kg/dan ter 90 mg irbesartana in 90 mg hidroklorotiazida na kg/dan, so se po znižanju krvnega tlaka (pri čemer niso opazili pomembnih toksikoloških interakcij) zaradi uporabe ene učinkovine ali kombiniranega dajanja pojavile naslednje spremembe:
The following changes, observed in rats and macaques receiving the irbesartan/hydrochlorothiazide combination at 10/10 and 90/90 mg/kg/day, were also seen with one of the two medicinal products alone and/or were secondary to decreases in blood pressure (no significant toxicologic interactions were observed):
Pri podganah in opicah, ki so prejemale kombinacijo 10 mg irbesartana in 10 mg hidroklorotiazida na kg/dan ter 90 mg irbesartana in 90 mg hidroklorotiazida na kg/dan, so se po znižanju krvnega tlaka (pri čemer niso opazili pomembnih toksikoloških interakcij) zaradi dajanja ene učinkovine ali kombinacije dveh učinkovin pojavile naslednje spremembe:
The following changes, observed in rats and macaques receiving the irbesartan/hydrochlorothiazide combination at 10/10 and 90/90 mg/kg/day, were also seen with one of the two medicinal products alone and/or were secondary to decreases in blood pressure (no significant toxicologic interactions were observed): kidney changes, characterized by slight increases in serum urea and creatinine, and hyperplasia/hypertrophy of the juxtaglomerular apparatus, which are a direct consequence of the interaction of irbesartan with the renin-angiotensin system;
Pri podganah in opicah, ki so prejemale kombinacijo 10 mg irbesartana in 10 mg hidroklorotiazida na kg/dan ter 90 mg irbesartana in 90 mg hidroklorotiazida na kg/dan, so se po znižanju krvnega tlaka (pri čemer niso opazili pomembnih toksikoloških interakcij) zaradi uporabe ene učinkovine ali kombiniranega dajanja pojavile naslednje spremembe:
The following clinical signs were observed after 3 or 5 times overdosing in dogs: softened or liquid faeces, vomiting, salivation, anorexia, severe weight loss, emaciated appearance, dehydration and pale mucosae.
Pri psih so po 3- do 5-kratnem prevelikem odmerjanju opazili naslednje klinične znake: zmehčano ali tekoče blato, bruhanje, slinjenje, anoreksija, huda izguba telesne teže, videz izčrpanosti, dehidracija in blede sluznice.
The following conditions have been reported to occur or deteriorate with both pregnancy and COC use, but the evidence of an association with COC use is inconclusive: Jaundice and/or pruritus related to cholestasis; gallbladder disease including cholecystitis and cholelithiasis; porphyria; systemic lupus erythematosus; haemolytic ureamic syndrome; Sydenham’s chorea; herpes gestationis; otosclerosis-related hearing loss.
Poročali so, da se tako med nosečnostjo kot tudi med jemanjem KPKS naslednja stanja bodisi pojavijo bodisi poslabšajo, niso pa dokazali, da so povezana z jemanjem KPKS: zlatenica in/ali pruritus, povezan s holestazo, bolezni žolčnika, vključno s holecistitisom in holelitiazo, porfirija, sistemski lupus eritematozus, hemolitičnouremični sindrom, Sydenhamova horea, pemfigoid (herpes gestationis), izguba sluha povezana z otosklerozo.
The following conditions have been reported to occur or deteriorate with both pregnancy and COC use, but the evidence of an association with COC use is inconclusive: jaundice and/or pruritus related to cholestasis; gallstone formation; porphyria; systemic lupus erythematosus; haemolytic uraemic syndrome; Sydenham’s chorea; herpes gestationis; otosclerosis-related hearing loss.
Poročali so, da se naslednje bolezni ali motnje pojavijo ali poslabšajo med nosečnostjo in med uporabo COC, vendar dokazi o povezavi s COC niso dokončni: zlatenica in/ali pruritus povezan s holestazo, nastanek žolčnih kamnov, porfirija, sistemski eritematozni lupus, hemolitično uremični sindrom, Sydenhamova horeja, herpes gestationis, izguba sluha zaradi otoskleroze.
The following conditions have been reported to occur or deteriorate with both pregnancy and COC use, but the evidence of an association with COC use is inconclusive: jaundice and/or pruritus related to cholestasis; gallstone formation; porphyria; systemic lupus erythematosus; haemolytic uraemic syndrome; Sydenham’s chorea; herpes gestationis; otosclerosis-related hearing loss.
Poročali so, da se naslednje bolezni ali motnje pojavijo ali poslabšajo med nosečnostjo in med uporabo KPK, vendar dokazi o povezavi s KPK niso dokončni: zlatenica in/ali pruritus povezan s holestazo, nastanek žolčnih kamnov, porfirija, sistemski eritematozni lupus, hemolitično uremični sindrom, Sydenhamova horeja, herpes gestationis, izguba sluha zaradi otoskleroze.
The following constituents of Poulvac FluFend H5N3 RG are included in Table 1 (Allowed substances) of the annex to Commission Regulation (EU) No 37/2010 as follows:
Naslednje sestavine zdravila Poulvac FluFenf H5N3 RG so vključene v tabeli 1 priloge Uredbe Komisije (EU) št.
The following convention has been used for classification of frequency:
Pogostnost je navedena v skladu z naslednjim dogovorom:
The following convention has been used for classification of frequency: Very common (≥1/10)
Kategorije pogostnosti so opredeljene kot: zelo pogosti (≥1/10),
The following convention has been used for the classification of adverse reactions very common
Pogostnost neželenih učinkov je razvrščena na naslednji način: zelo pogosti (≥ 1/10), pogosti (od
The following convention has been used for the classification of adverse reactions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100).
Neželeni učinki so razvrščeni po naslednjem dogovoru: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100).
The following convention has been used for the classification of adverse reactions: Very common (1/10)
Neželeni učinki so razvrščeni po skupinah po naslednjem dogovoru: zelo pogosti (1/10)
The following convention has been used for the classification of frequency:
Pogostnost je navedena v skladu z naslednjim dogovorom:
The following convention has been used for the classification of the adverse reactions (see table 1): very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000).
Za razvrstitev neželenih učinkov (glejte tabelo 1) je uporabljen naslednji dogovor: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000) in zelo redki (< 1/10.000).
The following convention has been used for the classification of the adverse reactions based on incidence rates in three phase III and two phase II clinical studies (see table 1): very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000).
Za razvrstitev neželenih učinkov, ki temeljijo na stopnjah incidence v treh kliničnih študijah III. faze in dveh kliničnih študijah II. faze (glejte tabelo 1), je uporabljen naslednji dogovor: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000) in zelo redki (< 1/10.000).
The following convention has been used for the classification of the adverse reactions: very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥ 1/1,000 to <1/100), rare (≥ 1/10,000 to <1/1,000) very rare (<1/10,000).
Za klasifikacijo neželenih reakcij smo uporabili naslednji dogovor: zelo pogosto (≥ 1/10), pogosto (≥ 1/100 do < 1/10), občasno (≥ 1/1.000 do < 1/100), redko (≥ 1/10.000 do < 1/1.000), zelo redko (< 1/10.000).
The following convention has been used for the classification of the adverse reactions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000).
Za klasifikacijo neželenih učinkov smo uporabili naslednji dogovor: zelo pogosto (≥ 1/10), pogosto (≥ 1/100 do < 1/10), občasno (≥ 1/1.000 do < 1/100), redko (≥ 1/10.000 do < 1/1.000), zelo redko (< 1/10.000).
The following convention has been utilised for the classification of frequency:
Pogostnost je navedena v skladu z naslednjim dogovorom:
The following convention has been utilised for the classification of frequency:
Za razvrstitev pogostnosti je uporabljen naslednji dogovor:
The following convention has been utilised for the classification of frequency: Very common (≥ 1/10), Common (≥ 1/100 to < 1/10), Uncommon (≥ 1/1,000 to < 1/100), Rare (≥ 1/10,000 to
Pogostnost je navedena v skladu z naslednjim dogovorom: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do
The following conventional classification is used: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Kategorije pogostnosti so opredeljene z naslednjim dogovorom: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
The following conventional classification is used: very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Kategorije pogostnosti so opredeljene z naslednjim dogovorom: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
The following conventional classification is used: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Uporabljena je naslednja običajna razvrstitev: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do <1/10), občasni (≥1/1.000 do < 1/100), redki (≥1/10.000 do <1/1.000), zelo redki (< 1/10.000), ni znano (ni mogoče oceniti na podlagi podatkov, ki so na voljo).
The following CTCAE (version 3.0) Grade 3 adverse reactions occurred in patients treated with abiraterone acetate: hypokalaemia 3%; urinary tract infection, alanine aminotransferase increased, hypertension, aspartate aminotransferase increased, fractures 2%; peripheral oedema, cardiac failure, and atrial fibrillation 1% each.
Pri bolnikih, ki so prejemali abirateronacetat, so se pojavili naslednji neželeni učinki 3. stopnje po CTCAE (verzija 3.0): hipokaliemija pri 3%; okužba sečil, zvišanje koncentracije alaninaminotransferaze, hipertenzija, zvišanje koncentracije aspartat-aminotransferaze, zlomi pri 2%, periferni edemi, srčno popuščanje in atrijska fibrilacija pri 1%.
The following data refer to the safety experience of oral CellCept in renal transplant patients.
Naslednji podatki se nanašajo na varnost peroralne oblike zdravila CellCept pri bolnikih z ledvičnim presadkom.
The following definitions apply to the frequency terminology used hereafter:
Pogostnosti so opredeljene z naslednjimi izrazi:
The following definitions apply to the frequency terminology used hereafter: Very common (≥1/10)
Naslednje opredelitve veljajo za uporabljeno terminologijo v zvezi s pogostnostjo: zelo pogosti (≥ 1/10);
The following definitions apply to the frequency terminology used hereafter: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to
V nadaljevanju se uporabljajo naslednje navedbe pogostnosti: zelo pogosti (≥ 1/10), pogosti (≥1/100 do
The following definitions apply to the frequency terminology used hereafter: Very common ( 1/10)
Za oznake pogostnosti veljajo naslednje definicije: Zelo pogosti (≥ 1/10)
The following definitions apply to the frequency terminology used hereafter: Very common ≥ 1/10;
V nadaljevanju se uporabljajo naslednje navedbe pogostnosti: Zelo pogosti ≥ 1/10
The following dosage schedule is suggested for initiation of therapy:
V nadaljevanju je navedeno odmerjanje, ki je priporočljivo za začetek zdravljenja.